NCT00571324View on ClinicalTrials.gov

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Congenital Hyperinsulinism
Interventions
DRUG

Exendin-(9-39)

A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.

OTHER

Vehicle

A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.

Trial Locations (1)

19104

The Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Diva De Leon

OTHER

NCT00571324 - Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism | Biotech Hunter | Biotech Hunter